This thesis focuses on the interplay between two Herpes Virus infections and the immunosuppression used after solid organ (and especially lung) transplantation. It starts with the description of diagnostic tools of Cytomegalovirus (CMV) and their therapeutic implications. Then it addresses the major clinical complication of a second herpes virus, the Epstein-Barr virus (EBV), namely Post Transplant Lymphoproliferative Disease (PTLD). These chapters describe the work done to come to a diagnostic tool to predict patients at risk for PTLD and they discuss clinical presentation and treatment of PTLD. We come to the new conclusion that EBV is associated with transplant dysfunction. We subsequently implemented a pre-emptive strategy for PTLD in our lung transplant program, and the results are shown in chapter 11 and 12. Finally, we propose that EBV DNA load can be used as a surrogate marker for over-immunosuppression after lung (and probably also other solid organ) transplantation, and, thus may help to guide and individualize immunosuppression. This summary contains two parts: the first part introduces the different chapters and describes their most important results, the second part summarizes the conclusions and speculates on the clinical implications and future perspective/research.
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.